Artiva Biotherapeutics Inc (ARTV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$11.19+0.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ARTV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -56.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ARTV — CEO transition
Dated 2026-05-19
Director and CFO — Diego Miralles, M.D. and Thad Huston: Dr. Diego Miralles resigned as a Director to take on an internal promotion, and Thad Huston departed from his CFO role with severance.
Why it matters: Leadership changes can impact company strategy and investor trust. Stability is key for growth.
Worry ifThe new CEO shares a clear plan that makes investors feel better.
Less concerning ifThere is more trouble with leadership or confusion from the new CEO.
Why it matters: The suspension may show a change in funding plans. It is important to know about future funding.
Watch forThe company announces a new plan for capital raising or funding.
Also watch forNo updates are given, or further issues arise from the suspension.
Why it matters: This data will show how well the company's treatments are working. Positive results could boost investor confidence.
Supportive ifManagement shows early data. The results for their treatments look good.
Worry ifNo data is released or results show poor clinical responses.
Why it matters: Maintaining a strong cash position is crucial for funding ongoing trials and operations. It signals financial health.
Supportive ifArtiva says its cash reserves are steady or growing. This will fund operations until 2029.
Worry ifCash reserves drop a lot or funding problems come up.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$271 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $969 loss on $10,000 · 9.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,922 loss on $10,000 · 49.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Changes in leadership can affect plans and actions. Stability helps keep investor trust.
Watch forArtiva has a strong new CFO. This will help keep operations running smoothly.
Also watch forThere are more executive exits. This may cause problems in leadership roles.
Why it matters: Good data can boost AlloNK's trust and draw in investors. It shows the therapy's promise.
Supportive ifArtiva shows good clinical data with ACR50 response rates over 50% at EULAR 2026.
Worry ifData shows ACR50 response rates under 50% or no important results.
Why it matters: Starting this trial is a key step for Artiva's growth strategy. It could validate AlloNK's effectiveness.
Supportive ifThe Phase 3 trial begins in the second half of 2026 as planned.
Worry ifThe trial is delayed beyond 2026 or not initiated.
Why it matters: Good data can increase trust in AlloNK's potential and draw more interest.
Supportive ifArtiva shows strong clinical data proving AlloNK works at EULAR 2026.
Worry ifThe data is weak or unclear. This lowers trust in AlloNK.
Why it matters: High ACR50 rates would show that AlloNK works well for treating tough RA.
Supportive ifThe Phase 3 trial shows ACR50 response rates above 50% at six months.
Worry ifThe response rate is under 50%. This raises worries about how well AlloNK works.
Why it matters: Starting this trial is key for Artiva's growth strategy. It shows progress in developing AlloNK.
Supportive ifThe Phase 3 trial begins as planned in the second half of 2026.
Worry ifThe trial is delayed or canceled, impacting the growth strategy.
Why it matters: A strong cash position supports ongoing trials and operations, crucial for growth.
Supportive ifCash reserves remain strong, funding operations into 2029 after the Phase 3 trial starts.
Worry ifCash reserves drop a lot. This raises worries about paying for future trials.